Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.
Giraldo P, Andrade-Campos M, Alfonso P, Irun P, Atutxa K, Acedo A, Barez A, Blanes M, Diaz-Morant V, Fernández-Galán MA, Franco R, Gil-Cortes C, Giner V, Ibañez A, Latre P, Loyola I, Luño E, Hernández-Martin R, Medrano-Engay B, Puerta J, Roig I, de la Serna J, Salamero O, Villalón L, Pocovi M. Giraldo P, et al. Among authors: barez a. Blood Cells Mol Dis. 2018 Feb;68:173-179. doi: 10.1016/j.bcmd.2016.10.017. Epub 2016 Oct 24. Blood Cells Mol Dis. 2018. PMID: 27836529 Free article.
Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma.
Puertas B, González-Calle V, Sobejano-Fuertes E, Escalante F, Queizán JA, Bárez A, Labrador J, Alonso-Alonso JM, García de Coca A, Cantalapiedra A, Villaescusa T, Aguilar-Franco C, Alejo-Alonso E, Rey-Bua B, López-Corral L, García-Sanz R, Puig N, Gutiérrez NC, Mateos MV. Puertas B, et al. Among authors: barez a. Cancers (Basel). 2023 Mar 2;15(5):1558. doi: 10.3390/cancers15051558. Cancers (Basel). 2023. PMID: 36900349 Free PMC article.
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, Mateos MV, Palomera L, Fernández-Calvo J, Martí JM, Giraldo P, Carbonell F, Callís M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J; Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA). Bladé J, et al. Among authors: barez a. Blood. 2005 Dec 1;106(12):3755-9. doi: 10.1182/blood-2005-03-1301. Epub 2005 Aug 16. Blood. 2005. PMID: 16105975 Free article. Clinical Trial.
The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis.
Paiva B, Vídriales MB, Pérez JJ, López-Berges MC, García-Sanz R, Ocio EM, de Las Heras N, Cuello R, García de Coca A, Pardal E, Alonso J, Sierra M, Bárez A, Hernández J, Suárez L, Galende J, Mateos MV, San Miguel JF. Paiva B, et al. Among authors: barez a. Blood. 2011 Mar 31;117(13):3613-6. doi: 10.1182/blood-2010-12-324665. Epub 2011 Jan 25. Blood. 2011. PMID: 21266717 Free article.
Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia.
Santamaría CM, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodriguez JN, Fernández-Abellán P, Bárez A, Peñarrubia MJ, Balanzategui A, Vidriales MB, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel JF, Gonzalez M. Santamaría CM, et al. Among authors: barez a. Blood. 2009 Jul 2;114(1):148-52. doi: 10.1182/blood-2008-11-187724. Epub 2009 Apr 27. Blood. 2009. PMID: 19398719 Free article.
The cellular origin and malignant transformation of Waldenström macroglobulinemia.
Paiva B, Corchete LA, Vidriales MB, García-Sanz R, Perez JJ, Aires-Mejia I, Sanchez ML, Barcena P, Alignani D, Jimenez C, Sarasquete ME, Mateos MV, Ocio EM, Puig N, Escalante F, Hernández J, Cuello R, García de Coca A, Sierra M, Montes MC, González-López TJ, Galende J, Bárez A, Alonso J, Pardal E, Orfao A, Gutierrez NC, San Miguel JF. Paiva B, et al. Among authors: barez a. Blood. 2015 Apr 9;125(15):2370-80. doi: 10.1182/blood-2014-09-602565. Epub 2015 Feb 5. Blood. 2015. PMID: 25655603 Free article.
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
González-López TJ, Alvarez-Román MT, Pascual C, Sánchez-González B, Fernández-Fuentes F, Jarque I, Pérez-Rus G, Pérez-Crespo S, Bernat S, Hernández-Rivas JA, Andrade MM, Cortés M, Gómez-Nuñez M, Olivera P, Martínez-Robles V, Fernández-Rodríguez A, Fuertes-Palacio MA, Fernández-Miñano C, de Cabo E, Fisac R, Aguilar C, Bárez A, Peñarrubia MJ, García-Frade LJ, González-Porras JR. González-López TJ, et al. Among authors: barez a. Eur J Haematol. 2016 Sep;97(3):297-302. doi: 10.1111/ejh.12725. Epub 2016 Jan 27. Eur J Haematol. 2016. PMID: 26709028
Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.
González-López TJ, Fernández-Fuertes F, Hernández-Rivas JA, Sánchez-González B, Martínez-Robles V, Alvarez-Román MT, Pérez-Rus G, Pascual C, Bernat S, Arrieta-Cerdán E, Aguilar C, Bárez A, Peñarrubia MJ, Olivera P, Fernández-Rodríguez A, de Cabo E, García-Frade LJ, González-Porras JR. González-López TJ, et al. Among authors: barez a. Int J Hematol. 2017 Oct;106(4):508-516. doi: 10.1007/s12185-017-2275-4. Epub 2017 Jun 30. Int J Hematol. 2017. PMID: 28667351 Clinical Trial.
51 results